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Toledo, Ohio; Kansas City, Missouri; Rochester, Minnesota; and Riyadh, Kingdom of Saudi ArabiaObjectives This study sought to perform a meta-analysis of randomized controlled trials comparing
device closure with medical therapy in the prevention of recurrent neurological events in patients with
cryptogenic stroke and patent foramen ovale.
Background The optimal strategy for secondary prevention of cryptogenic stroke with a patent
foramen ovale is unclear.
Methods Several databases were searched from their inception to March 2013, which yielded 3
eligible studies. The results were pooled as per the different patient populations deﬁned in the
studies:dintention-to-treat, per-protocol, and as-treated cohorts. A generic inverse method was used
based on time-to-event outcomes in a ﬁxed-effect model. A supplementary analysis pooled the results
from only 2 trials (RESPECT [Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to
Established Current Standard of Care Treatment] and PC Trial [Randomized Clinical Trial Comparing the
Efﬁcacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients
With Cryptogenic Embolism]) as a similar device was used in them.
Results Our meta-analysis yielded effect-estimate hazard ratios of 0.67 (95% conﬁdence interval [CI]:
0.44 to 1.00, I2 ¼ 0%) in the intention-to-treat cohort, 0.62 (95% CI: 0.40 to 0.95). I2 ¼ 0%) in the per-
protocol cohort, and 0.61 (95% CI: 0.40 to 0.95, I2 ¼ 38%) in the as-treated cohort, showing beneﬁcial
effects of device closure. The results became more robust with pooled results from RESPECT and the
PC Trial: The effect-estimate hazard ratios being 0.54 (95% CI: 0.29 to 1.01, I2 ¼ 0%), 0.48 (95% CI: 0.24
to 0.94, I2 ¼ 26%), and 0.42 (95% CI: 0.21 to 0.84, I2 ¼ 26%) in the intention-to-treat, per-protocol, and
as-treated populations, respectively.
Conclusions Our meta-analysis suggests that PFO closure is beneﬁcial as compared to medical
therapy in the prevention of recurrent neurological events. This meta-analysis helps to further
strengthen the role of device closure in cryptogenic stroke. (J Am Coll Cardiol Intv 2013;6:1316–23)
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Abbreviations
and Acronyms
CI = conﬁdence interval
HR = hazard ratio
OR = odds ratio
PFO = patent foramen ovale
TIA = transient ischemic
attack
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1317Stroke is among the leading causes of mortality and serious
long-term disability (1), with an estimated cost in terms of
healthcare services, medication, and missed days of work
being $38.6 billion each year in the United States alone (2).
Approximately 795,000 strokes occur annually in the United
States, with around 185,000 being recurrent attacks (3).
Around one-third of the patients hospitalized with stroke
are under the age of 65 years (4). Around 25% of all strokes
are cryptogenic, and this reaches approximately 50% in the
younger age group (5). Epidemiologic data reveal signiﬁcant
association between patent foramen ovale (PFO) and cryp-
togenic stroke both in the younger and older patient pop-
ulations (6,7). Despite medical therapy, the rate of stroke
recurrence in patients with PFO is estimated to be 25%
within a 4-year period (8,9).
Therefore, there has been signiﬁcant interest in percuta-
neous closure of PFO as a potential therapeutic option in
this group of patients. Observational data and meta-analyses
of observational studies suggest that percutaneous tran-
scatheter closure of PFO is safe and has a low recurrence
rate of stroke as compared to medical therapy (10–12).
However, so far, published randomized controlled studies
have not shown superiority of PFO closure over medical
therapy (13–15).
The ﬁrst trial presented on this issuedCLOSURE I
(Evaluation of the STARFlex Septal Closure System in
Patients With a Stroke and/or Transient Ischemic Attack due
to Presumed Paradoxical Embolism Through a Patent
Foramen Ovale)dfailed to show any beneﬁt of device closure
(16). The CLOSURE I trial had several limitations that
challenge the applicability of its outcome, namely: sluggish
recruitment; off-label closure; inclusion of transient ischemic
attack (TIA) causing heterogeneity in the patient population;
and use of a device associated with a higher rate of peri-
procedural complications than that of current-generation
devices (16). Speciﬁcally, the STARFlex device (NMT
Medical Inc., Las Vegas, Nevada) used in the trial had a lower
successful closure rate and an increased incidence of peri-
procedural atrial ﬁbrillation (17), which may have contrib-
uted to a higher-than-expected event rate in the device
group. Two other randomized controlled trials have recen-
tly been published (14,15). These were the RESPECT
(Randomized Evaluation of Recurrent Stroke Comparing
PFO Closure to Established Current Standard of Care
Treatment) trial and the PC Trial (Percutaneous Closure
of PFO Using the Amplatzer PFO Occluder With Medical
Treatment in Patients With Cryptogenic Embolism), which
was a clinical trial. Both these trials trended toward
a beneﬁcial effect of device closure as compared to medical
therapy, but the magnitude of effect estimate was low. It has
been thought that the main limitation of these studies was
modest statistical power (18).
Thus, the optimal strategy for secondary prevention in
patients with cryptogenic stroke with a PFO remainsunclear. Given this ongoing controversy, we performed a
systematic review and meta-analysis that addressed the role
of device closure versus medical therapy in cryptogenic
stroke with PFO.Methods
Data sources and search strategy. The systematic review was
carried out in accordance to the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses) guidelines (19). The search strategy and subsequent
literature searches were performed by an experienced
medical reference librarian (P.J.E.). The search strategies
were developed in Ovid Medline, and translated to match
the subject headings and key words for Ovid Embase,
Cochrane Central, ISI Web of Science, and Scopus from
database inception through March 21, 2013. The following
MeSH, Emtree, and search word terms were used in
combination: “patent foramen ovale”; “PFO”; “right to left
shunt”; “atrial septal aneurysm”; “interatrial shunt”; “ASA”
and “stroke”; “ischemic stroke”; “cryptogenic stroke”; “CVA”;
“recurrent stroke”; “transient
ischemic attack”; “TIA”; “brain
infarction” and “medical therapy”;
“platelet aggregation”; “anticoag-
ulants”; “percutaneous closure”;
“transcatheter closure”; “cardiac
catheterization”; “septal occluder
device” and “controlled trials”;
“intervention study;” “random-
ized controlled trial.” There
was no restriction of language.
To identify further articles, we searched for meeting abstracts
in Embase and hand-searched references and related citations
in review articles and commentaries. All results were down-
loaded into EndNote (Thompson ISI ResearchSoft, Phila-
delphia, Pennsylvania), a bibliographic databasemanager, and
duplicate citations were identiﬁed and removed.
Study selection. Two authors (A.R.K. and S.K.) indepen-
dently assessed the eligibility of identiﬁed studies. The
results that were further evaluated were limited to random-
ized controlled trials that focused on comparison of medical
therapy versus percutaneous closure of PFO in patients with
cryptogenic stroke.
Data extraction. Two reviewers (A.R.K. and A.B.) inde-
pendently extracted data on a pre-deﬁned data-collection
form. Extracted data included the following: population
under study; subject characteristics; type of medical therapy
or device used; and data on efﬁcacy and safety. The outcome
was accepted as deﬁned in individual trials and related to the
recurrence of stroke, TIA, or all-cause mortality. Data on
safety included adverse events reported due to the device or
medical therapy.
Figure 1. Flow Diagram of Eligible Studies
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1318Quality assessment. Two reviewers (S.K. and A.B.) inde-
pendently assessed the methodological quality of selected
studies using the Jadad scale. This scale is used to explore
adequate randomization, blinding, and description of with-
drawal or dropout (20).
Data synthesis and statistical analysis. Our intention was to
investigate whether percutaneous closure of PFO is superior
to medical therapy in patients with cryptogenic stroke. Data
on efﬁcacy and safety were analyzed and pooled separately.
EFFICACY. All the included studies reported time-to-event
outcomes using Cox proportional hazard ratios (HRs).
CLOSURE I reported its results as time-to-event out-
comes in intention-to-treat, modiﬁed intention-to-treat, and
per-protocol populations. The modiﬁed intention-to-treat
population was described as having received the study
treatment regardless of the follow-up, whereas the per-
protocol population had at least 22 months of follow-up
after the randomly assigned treatment. RESPECT pre-
sented its analysis as raw count analysis in an intention-
to-treat population. They also performed a survival analysis
with time-to-event outcome because of unequal dropout
rates between the 2 groups in order to provide an exposure-
stratiﬁed comparison. They also reported results in 2 pre-
speciﬁed populationsdper-protocol and as-treated cohorts.
The per-protocol population received the randomly assigned
treatment, whereas the as-treated population was classiﬁed
according to the treatment actually received regardless of the
randomization. The PC Trial also reported time-to-event
outcomes as per intention-to-treat and per-protocol pop-
ulations. The per-protocol population deﬁned here received
the randomly assigned treatment.
The meta-analysis was done using a ﬁxed-effect model. A
generic inverse variance method was used based on time-to-
event outcomes reported. The results were pooled according
to the different populations speciﬁed in the reported
trialsdas intention-to-treat, per-protocol, and as-treated
populations. CLOSURE I and the PC Trial did not report
results as as-treated, so the as-treated analysis was performed
using intention-to-treat outcomes in the cohort.
We performed a supplementary analysis pooling the
results from RESPECT and the PC Trial only, as a similar
device was used in both trials.
SAFETY. Data on safety was analyzed as the total number
of adverse events, atrial ﬁbrillation, and bleeding out-
comes. For atrial ﬁbrillation, a sensitivity analysis was
done after exclusion of data from CLOSURE I as the
STARFlex device used appeared to cause a signiﬁcant
proportion of peri-procedural atrial ﬁbrillation and has
since been discontinued. A ﬁxed-effects model was used
with the Mantel-Haenszel method with nonﬁxed zero-
cell correction to pool data. This method is recommended
whenever sparse data is pooled (21). There was some
heterogeneity found in the atrial ﬁbrillation and bleedingoutcomes; hence, a random-effects model and the
Mantel-Haenszel method with continuity correction were
used to account for it.
Cochran’s Q test was used to assess heterogeneity among
studies and was complemented by the I2 statistic. The I2
statistic describes the proportion of variation in treatment
estimate that is not related to sampling error (22). All
analyses were conducted using the statistical software
RevMan (Version 5.2. Copenhagen, Denmark: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012).
Results
Identiﬁcation of studies. The literature search identiﬁed 504
publications, out of which 3 were eligible for inclusion in the
analysis (Fig. 1) (13–15). All the included studies scored 3
on the Jadad scale. There was excellent agreement for the
inclusion of the studies, data abstraction, and quality
assessment between the reviewers (kappa statistics being 1.0,
0.92, and 1.0, respectively).
Study characteristics. Table 1 summarizes the characteristics
of the included studies. The studies were conducted in the
United States, Canada, United Kingdom, Europe, Brazil,
and Australia. Thus, 3 studies comprising 2,303 participants
included in the analysis. The relevant outcomes of interest in
Table 1. Characteristics of the Randomized Controlled Trials
CLOSURE I (13) RESPECT (14) PC Trial (15)
Trial design Prospective, 2-arm superiority trial Event-driven, prospective, 1:1 randomized,
stratiﬁed by site and ASA
Prospective, parallel assignment,
safety and efﬁcacy study
Publication of results Published: N Engl J Med, March 2012 Published: N Engl J Med, March 2013 Published: N Engl J Med, March 2013
Centers Multicenter: 87 sites (United States and
Canada)
Multicenter: 69 sites (United States and
Canada)
Multicenter: 29 sites (Europe, United
Kingdom, Australia, Brazil, and Canada)
Participants 909 980 414
Inclusion criteria Age 18 to 60 yrs; history of an ischemic
stroke or TIA within the previous 6 months;
evidence of a PFO, as documented by TEE
with a bubble study
Age 18 to 60 yrs with PFO; history of a
cryptogenic stroke within 270 days
Age <60 yrs; presence of PFO  ASA;
ischemic stroke/TIA or extracranial
peripheral thromboembolismdclinically
and radiologically proven
Exclusion criteria Identiﬁable cause of ischemic stroke/TIA; another
source of R/L shunt, an acute or recent
MI/unstable angina; LV aneurysm/akinesis;
intracardiac thrombus or tumor
Cerebral/cardiovascular, and systemic
conditions that suggest other mechanisms
for stroke; contraindication to medical/
device therapy; limited life expectancy,
inability to attend follow-up
Identiﬁable cause for thromboembolic event;
contraindication/other indication to
medical therapy; previous PFO closure;
CNS disease
Device closure STARFlex septal closure system
(NMT Medical Inc., Boston, MA)
Amplatzer PFO Occluder (AGA Medical Corp.,
Golden Valley, MN)
Amplatzer PFO Occluder (AGA Medical Corp.,
Golden Valley, MN)
Medical therapy Warfarin (INR: 2 to 3); aspirin 325 mg/d or both Aspirin, warfarin, clopidogrel, aspirin with
dipyridamole, or aspirin with clopidogrel*
Antiplatelet therapy or oral anticoagulation
as per the discretion of the treating
physician
Follow-up 2 yrs Until 25th primary endpoint Up to 5 yrs
Primary endpoint Composite of stroke or TIA, death from any
cause (30 days), death from neurologic causes
(31 days to 2 yrs)
All-cause mortality; recurrence of fatal or
nonfatal ischemic stroke
Composite of death from any cause,
nonfatal stroke, TIA, and peripheral
embolism
Secondary endpoint Major bleeding; death from any cause; stroke,
TIA, and transient neurologic events
of uncertain cause
Complete closure of the defect; absence of
recurrent cryptogenic nonfatal
stroke/TIA or cardiovascular death
MI and peripheral thromboembolism; new
arrhythmia (AF); rehospitalization related
to PFO or its Rx; device-related problems
*Aspirin with clopidogrel was removed from the protocol in 2006 based on changes to the American Heart Association/American Stroke Association treatment guidelines.
AF ¼ atrial ﬁbrillation; ASA ¼ atrial septal aneurysm; CLOSURE I ¼ Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack due to Presumed
Paradoxical Embolism Through a Patent Foramen Ovale; CNS ¼ central nervous system; INR ¼ international normalized ratio; LV ¼ left ventricular; MI ¼ myocardial infarction; PC Trial ¼ Percutaneous
Closure of Patent Foramen Ovale (PFO) Using the Amplatzer PFO Occluder With Medical Treatment in Patients With Cryptogenic Embolism; PFO ¼ patent foramen ovale; RESPECT ¼ Randomized
Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment; R/L ¼ right-to-left; Rx ¼ prescription drug; TEE ¼ transesophageal echocardiography;
TIA ¼ transient ischemic attack.
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1319all studies were the development of fatal or nonfatal ischemic
stroke and all-cause mortality. CLOSURE I and the PC
Trial also had TIA as a primary endpoint, which differs from
the RESPECT trial (Table 1).
Meta-analysis. EFFICACY. Our meta-analysis yielded
a pooled effect-estimate HR of 0.67 (95% conﬁdence
interval [CI]: 0.44 to 1.00, I2 ¼ 0%) in the intention-to-
treat cohort, suggesting a protective effect of device closure
in the incidence of recurrent stroke in patients with PFO as
compared to medical therapy. The pooled effect-estimate
HR was 0.62 (95% CI: 0.40 to 0.95), I2 ¼ 0%) using the
per-protocol cohort and was 0.61 (95% CI: 0.40 to 0.95,
I2 ¼ 38%) using the as-treated cohort, showing a beneﬁcial
effect of device closure (Fig. 2).
The results become more robust when we pooled
results from RESPECT and the PC Trial. The pooled
effect-estimate HRs were 0.54 (95% CI: 0.29 to 1.01,
I2 ¼ 0%), 0.48 (95% CI: 0.24 to 0.94, I2 ¼ 0%), and 0.42
(95% CI: 0.21 to 0.84, I2 ¼ 26%) in the intention-to-
treat, per-protocol, and as-treated populations, respec-
tively (Fig. 3).SAFETY. The overall risks for adverse events were similar in
both the device closure and the medical therapy groups: odds
ratio (OR) 1.11 (95% CI: 0.91 to 1.35, I2 ¼ 0%). The
incidence of atrial ﬁbrillation was found to be higher in the
device group as compared to medical therapy (OR: 3.29,
95% CI: 0.86 to 12.6, I2 ¼ 60%). The sensitivity analysis
performed after the exclusion of CLOSURE I showed the
incidence decreases and is not statistically signiﬁcant (OR:
1.81, 95% CI: 0.60 to 5.42, I2 ¼ 4%). The incidence of
bleeding episodes were also not signiﬁcantly different
between the 2 groups (OR: 1.43, 95% CI: 0.47 to 4.42,
I2 ¼ 49%) (Fig. 4).
Discussion
Findings. The ﬁndings from our systematic review and
meta-analysis suggest that device closure may have a bene-
ﬁcial effect in preventing recurrent neurological events in
patients with cryptogenic stroke and PFO. The effect esti-
mate reveals a 33% to 39% reduction in the hazard for
a recurrent neurological event depending on the population
Figure 2. Forest Plot Comparing the Efﬁcacy of Device Closure Arm and Medical Therapy Arm
Stratiﬁed based on intention-to-treat, per-protocol, and as-treated cohorts. CI ¼ conﬁdence interval; CLOSURE I ¼ Evaluation of the STARFlex Septal Closure System in
Patients With a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale (PFO) (16); df ¼ degrees of freedom;
PC Trial ¼ Percutaneous Closure of Patent Foramen Ovale Using the Amplatzer PFO Occluder With Medical Treatment in Patients With Cryptogenic Embolism (14);
RESPECT ¼ Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (15); SE ¼ standard error.
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only the Amplatzer device, the beneﬁt becomes more
apparent, with a reduction of approximately 46% to 58%.
The safety of the device was comparable to medical therapy,
with a low incidence of adverse events.
Not only did all the analyses have effect estimates in favor
of device closure, the pooled results also conﬁrmed a more
signiﬁcant beneﬁcial effect. As mentioned, the trials most
likely did not meet their expected outcome because of low
numbers of enrolled patients, lower-than-expected event
rates, and relatively short follow-up. All the reported studies
had difﬁculty in enrollment. The trials were also performed
in an environment of signiﬁcant off-label closure (23). In
addition to the total number of subjects enrolled, this likely
led to a selection bias in which the enrolled population may
not be representative of the groups most likely to beneﬁt
from PFO closure. This also may have diluted the actual
beneﬁcial effect of device closure in randomized patients.Moreover, follow-up of study patients was likely too short
to assess a signiﬁcant difference in efﬁcacy between the 2
groups. Observational data has demonstrated that event rates
in medical therapy versus device closure appeared to separate
after 2 years of follow-up (10). Recently, a propensity-
matched comparison cohort showed that mortality or stroke
beneﬁt becomes more apparent in long-term follow-up (11).
Data from RESPECT showed the same trend, with the
curves continuing to diverge more after 2 years and
continuing to diverge even at 5 years. The Kaplan-Meier
curves in individual trials continued to diverge, suggesting
that the postulated beneﬁt may need more time to become
signiﬁcant.
Strengths of our analysis. To the best of our knowledge,
this is the ﬁrst systematic review and meta-analysis of
randomized controlled trials to compare the efﬁcacy and
safety of device closure with medical therapy in cryptogenic
stroke with PFO. Our results are consistent with a previous
Figure 3. Forest Plot Comparing the Efﬁcacy of Device Closure Arm and Medical Therapy Arm: Pooled Analysis of RESPECT and the PC Trial
Stratiﬁed based on intention-to-treat, per-protocol, and as-treated cohorts. Abbreviations as in Figure 2.
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1321observational data (24–27) and meta-analysis (12,28) in
terms of safety and efﬁcacy. Agarwal et al. (12) also reported
a beneﬁcial effect of transcatheter closure of PFO as
compared to medical therapy in reduction of recurrent
neurological events. Their analysis was based on non-
randomized evidence derived from observational studies.
Another analysis by Kitsios et al. (29) compared observa-
tional evidence with the only available randomized trial
(CLOSURE I) presented at that time. They found
a difference in the number of events between randomized
and observational evidence. The device group in
CLOSURE I had a higher incidence of events as compared
to the observational data. First, this can be explained by the
use of the STARFlex device, which had a higher incidence
of peri-procedural atrial ﬁbrillation and complications.
Second, observational study design may have led to inclusion
bias. Our analysis included only randomized controlled
trials. We also performed a separate analysis excluding the
CLOSURE I trial.
Limitations of our analysis. The results of our meta-analysis
are weakened by limitations inherent to meta-analyses and
to the included studies. The low number of included studies
leads to low statistical power, especially for safety data
analysis. The analysis of rare events is associated with its ownlimitations, where even a small change in the number of
events can produce a dramatic change in the results (30).
There was a lack of individual patient data, which may have
affected the results of our analysis. Medical therapy was not
uniform across the trials and even within trials, which may
have had an effect on neurological events. Our pooled effect
estimate has included trials that differ in the baseline risks of
patients, devices used, and clinical endpoints measured that
can be considered as a weakness of our analysis. However, it
can be argued that it extends the generalizability of our
ﬁndings to a wider range of population.
Future directions. There remain several unanswered ques-
tions in the ﬁeld of cryptogenic stroke. It has been shown
that not all ischemic strokes with a PFO will beneﬁt from
closure. High-risk subgroups that may beneﬁt from device
closure need to be deﬁned further. One approach of iden-
tifying such high-risk subgroups is risk modeling. The
RoPE (Risk of Paradoxical Embolism) study is currently
being performed to develop models to identify PFO-related
cryptogenic strokes and the risk of their recurrence (31).
Another approach would be to pool patient-level data, which
might help in identiﬁcation of high-risk subgroups. In-
dividual data meta-analysis is especially helpful when the
effect of individual patient characteristics on the treatment is
Figure 4. Forest Plot Comparing the Safety of Device Closure With Medical Therapy
Stratiﬁed based on intention-to-treat, per-protocol, and as-treated cohorts. The pooled analysis of atrial ﬁbrillation was done with inclusion of all 3 trials and then with
only RESPECT and PC trials. M.-H. ¼ Mantel-Haenszel; other abbreviations as in Figure 2.
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1322being investigated (32). It would help to assess variation in
treatment effect in patients with variation in individual
characteristics. Should future randomized trials be contem-
plated, then efforts should be undertaken to ensure that
enrolled patients are truly representative of the cryptogen-
ic stroke population to avoid exclusion of the high-risk
groupdthe particular population most likely to beneﬁt from
device therapy.
With the evidence available thus far, it may be more
appropriate that individual patient characteristics, their
clinical presentation, and structural assessment of the shunt
be the subjects of a thorough discussion between the treating
physicians and their patients concerning the risks, beneﬁts,
and alternatives of device closure. This will allow for iden-
tiﬁcation of the most appropriate clinical scenarios for
percutaneous closure of PFO.
Conclusions
Our meta-analysis suggests that percutaneous device closure
for PFO is beneﬁcial as compared to medical therapy in the
prevention of recurrent cryptogenic stroke. This meta-
analysis helps to further strengthen the role of device closurein cryptogenic stroke. The precise patient population likely
to beneﬁt most from device therapy is yet to be deﬁned.
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